We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Screening for Genetic Mutations Predict Preterm Birth Defects

By Biotechdaily staff writers
Posted on 12 Feb 2008
Genetic mutations in the enzyme methylenetetrahydrofolate reductase (MTHFR) and coagulation protein factor V appear to have significant association with blood clots and tissue injury to the placenta and developing baby.

MTHFR is an enzyme related to amino acid metabolism. More...
Intrauterine growth restriction results in malnutrition of the developing fetus and babies of low birth weight, and can be related to a host of factors usually reflective of the mother's health, including infection, high blood pressure, and use of tobacco, alcohol, or illicit drugs. Factor V is a protein of the coagulation system, sometimes referred to as proaccelerin or labile factor.

Defined as any birth prior to 37 weeks gestation, preterm birth affects some 12% of pregnancies in the United States. A recent study from the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) found that preterm birth contributed to more than a third of infant deaths--twice as many as previously thought and making it the leading cause of infant deaths --yet the underlying causes of premature birth remain poorly understood. Babies who do survive face risks related to cerebral palsy, mental retardation, chronic lung disease, and vision and hearing loss, as well as other developmental problems.

Scientists from the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) analyzed DNA from placental tissue samples and cord blood from 111 women and their babies, finding that one fetal single nucleotide polymorphism (SNP) in MTHFR and one fetal SNP in factor V demonstrated "highly significant association with thrombotic and inflammatory lesions,” irrespective of adjustment for maternal race, smoking, and lower genital tract infection, all of which can contribute to genetic mutation. Women and babies with MTHFR mutation were 4.2 times more likely to exhibit blood clots and injury to placental tissue than those without the mutation. For those with factor V mutation, the association was less pronounced, but still elevated.

"This indicates a possible genetic predisposition to a condition of real clinical consequence in terms of intrauterine growth restriction, preeclampsia, and spontaneous preterm birth,” said Hyagriv Simhan, M.D., assistant professor of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh School of Medicine.

The study was presented at the 28th annual meeting of the Society for Maternal-Fetal Medicine, which was held in Dallas (TX, USA) from January 28 to February 2, 2008.


Related Links:
U.S. Centers for Disease Control and Prevention
University of Pittsburgh School of Medicine

New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pipette
Accumax Smart Series
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.